Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVA186)

Drug Name

R7334 Drug Info

Synonyms

R 7334; 2-Nitro-6,7,8,9-tetrahydronaphtho(1,2-b)furan; 2-nitro-6,7,8,9-tetrahydrobenzo[g][1]benzofuran; 6,7,8,9-Tetrahydro-2-nitronaphtho(1,2-b)furan

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Placenta growth factor (PlGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[3]
RO-5323441	DMUB3OY	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
TB-403	DMDPBMH	Glioblastoma of brain	2A00.00	Phase 2	[5]
SFLT-01	DMD2GKF	Macular degeneration	9B78.3	Phase 1	[6]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00702494) Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Roche (2009).
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.